Cell-Based Endosomal Transport Assay for Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for assessing the delivery efficiency of molecules into eukaryotic cells, particularly those using receptor-mediated endocytosis, face challenges such as high animal welfare concerns, requirement for large animal numbers, and limited ability to evaluate cell binding, endosome formation, and translocation across the endosomal membrane, leading to unreliable potency results.
Innovation Solution
A novel assay involving eukaryotic cells with a binding site on their surface, where the test molecule binds, undergoes endocytosis, and is detected in endosomes or the cytosol, allowing for the calculation of an endosome release value by comparing the amount of test molecule before and after a predetermined incubation period, providing a humane and reliable assessment of potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional assays (LD50, mouse flaccid paralysis, hemi-diaphragm) are used to assess molecule potency, then potency can be evaluated, but large numbers of animals are required and animal welfare is compromised
Solution Approach 1:
The patent uses cell-based assays as a copy model of in vivo potency testing. Instead of using whole animals, the invention employs eukaryotic cells that replicate the key biological processes (endocytosis, endosomal transport, cytosolic release) to assess molecule potency. This cellular model maintains assay reliability while eliminating the need for animal testing.
Solution Approach 2:
The patent extracts and isolates the specific biological processes relevant to potency assessment from the complex in vivo system. By focusing solely on endocytosis, endosomal transport, and cytosolic release in isolated eukaryotic cells, the invention separates the essential potency-determining steps from the unnecessary animal system, achieving both reliability and animal welfare protection.
2Reliability
If traditional assays are used, then potency can be assessed, but the assays are time-consuming and require large animal numbers
Solution Approach 1:
The patent creates a simplified cellular copy of the potency assessment process that can be performed in parallel for multiple molecules. Eukaryotic cell-based assays enable high-throughput screening by replacing time-consuming in vivo animal tests with rapid cellular processes that can be automated and scaled.
Solution Approach 2:
The patent segments the potency assessment into distinct measurable steps: binding to cell surface receptors, endocytosis into endosomes, transport across the endosomal membrane, and release into the cytosol. This segmentation allows each step to be independently optimized and measured, improving assay efficiency and throughput.
3Reliability
If existing assays are used, then potency can be evaluated, but they cannot comprehensively assess all steps of endocytosis and translocation
Solution Approach 1:
The patent divides the molecule delivery process into four distinct segments: (1) binding to cell surface receptors, (2) endocytosis into endosomes, (3) translocation across the endosomal membrane, and (4) release into the cytosol. Each segment can be independently detected and measured using specific cellular markers and imaging techniques, providing comprehensive information that was previously lost in traditional assays.
Solution Approach 2:
The patent introduces specific intermediary markers and detection methods for each step of the process. For example, fluorescently labeled molecules can track endocytosis, while pH-sensitive dyes can indicate endosomal location, and cytosolic enzyme activity can confirm translocation. These intermediaries provide detailed information about each step without interfering with the overall process.
4Reliability
If traditional assays are used, then potency can be measured, but the results are highly dependent on assay conditions and lack standardization
Solution Approach 1:
The patent standardizes potency measurement by controlling and reporting specific cellular parameters: cell type, receptor density, incubation temperature, pH levels, and time points. By fixing these parameters and providing reference ranges, the invention enables precise and comparable potency measurements across different laboratories and assay conditions, eliminating the variability that plagues traditional methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This assay offers a humane and reliable method to assess the potency of molecules by quantifying their endosome release and cytosolic presence, addressing the limitations of existing assays and providing a comprehensive evaluation of molecular delivery efficiency.
Implementation Method 1
the test molecule binds to a binding site (e.g. a receptor or acceptor) present on the cell surface. In step 2, the receptor (plus bound molecule) becomes internalised into the cell - this step is generally referred to as 'endocytosis' or 'endosome formation'
Implementation Method 2
In step 3, following internalisation, the molecule inserts into the endosomal membrane, and effects release of the molecule (or a part thereof) from within the endosome, across the endosomal membrane and into the cytosol of the eukaryotic cell
Data Source
AI summary
The invention provides an assay and corresponding kit for assessing the delivery efficiency of a molecule into a eukaryotic cell (basic assay). The present invention also provides an assay and corresponding kit for assessing the inhibitory effect of a test molecule in relation to the before-mentioned basic assay.